


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-18. (Canceled)


19. (Currently Amended) A compound represented by the general formula (I)



Formula I

wherein:

X is the following radical:



L is independently selected from $-C(R)(R')$ -, $-CO$ -, $[-O-]$ and $-NR'$ -;

n is zero, one, two, three, four, five, six, seven, eight, nine or ten;

R and R' are independently selected from hydrogen, $[I]$ and alkyl-, aryl-, heteroaryl-, halo-, haloalkyl-, alkoxy-, hydroxyl-, nitro- and alkylthio

D is independently selected from $-C(R_9)$ -, wherein R_9 is hydrogen; and $[-C=, \text{ or}] -N$ -;

$A_1, A_2, A_3, A_4, A_5, A_7, A_8$, ~~E and G~~ are independently selected from $[-CO-]$, $[-C(R_{10})(R_{11})-[I]]$ and $=C(R_{10})$ -, $-N(R_{12})$ -, $-O$ -, $-S(O)_1$ -;

each of E and G is, independently, $-CO$ - or $-CH_2$ -;

R_1, R_2, R_3 , and R_4, R_9, R_{10} and R_{11} are independently selected from hydrogen, $[I]$ and alkyl-, alkoxy-, and hydroxyl-, alkylthio-, cycloalkyl-, haloalkyl-, halo-, aryl-, $(Z)_n$ -aryl-, heteroaryl-, $O(R_7)$ -, $C(O)R_7$ -, $C(O)OR_7$ -, $S(O)_6$ -, cyano-, nitro- and mercapto-, aryl-substituted by alkyl-, alkoxy-, hydroxy-, halo-, haloalkyl-, nitro- or alkylthio; and heteroaryl substituted by alkyl-, alkoxy-, hydroxy-, halo-, haloalkyl-, nitro- or alkylthio

R_{10} and R_{11} are independently selected from hydrogen and halo;


Z is independently selected from $-C(R_7)(R_8)$ -, $-C(O)$ -, $-O$ -, $-C(=NR_7)$ -, $-S(O)_6$ -, $-N(R_7)$ -

R_7 - and R_8 - are independently selected from hydrogen, alkyl-, alkoxy-, alkylthio-, cycloalkyl-, haloalkyl-, halo-, aryl-, heteroaryl-, cyano-, nitro-, mercapto-, aryl-substituted by alkyl-, alkoxy-,

hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

t — is zero, one or two;

with the exclusion of the following two compounds:



20. (Currently Amended) A compound according to claim 19, wherein X is selected from phthalimide (1,3-dioxo-1,3-dihydro-indole-2-yl), indol-2-yl, 1-indanon-2-yl, benzimidazol-2-yl, and indandion-2-yl, indazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, or benzotriazol-2-yl.

21. (Previously Presented) A compound according to claim 19, wherein X is phthalimide (1,3-dioxo-1,3-dihydro-indole-2-yl) and the cyclic part of formula I represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro, 1,2,3,4-tetrahydro-acridin-9-yl.

22. (Previously Presented) A compound according to claim 19 which is:

- 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
- 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
- 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
- 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),

- N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
- N-(3-{[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
- 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),
- 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), or
- 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5).

23. (Previously Presented) A compound according to claim 19, wherein X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl.

24. (Previously Presented) A compound according to claim 23, which is:

- 5,6-Dimethoxy-2-{{[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl}-indan-1-one (1) or
- 5,6-Dimethoxy-2-{{[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl}-indan-1-one (2).

25. (Previously Presented) A pharmaceutical formulation containing as active ingredient a compound as defined in claim 19.

26. (Withdrawn-amended) A method of treating a cognitive disorder, which comprises ~~administering~~ administering an effective amount of a compound as defined in claim 19.

27. (Withdrawn) The method of claim 26, wherein the cognitive disorder is senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, or a neurodegenerative dementing disease with aberrant protein aggregations.

28. (Withdrawn) The method of claim 27, wherein the neurodegenerative dementing disease with aberrant protein aggregations is Alzheimer's disease, Parkinson disease, ALS, or prion diseases.

29. (Withdrawn) The method of claim 28, wherein the prion disease is Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.